Welcome to our dedicated page for 89Bio news (Ticker: ETNB), a resource for investors and traders seeking the latest updates and insights on 89Bio stock.
89Bio, Inc. (NASDAQ: ETNB) is a clinical-stage biopharmaceutical company pioneering therapies for liver and cardiometabolic diseases, with its lead candidate pegozafermin advancing through Phase 3 trials. This page serves as the authoritative source for all official company updates, including clinical developments, regulatory milestones, and strategic partnerships.
Investors and researchers will find timely updates on-therapeutic progress for metabolic dysfunction-associated steatohepatitis (MASH) and severe hypertriglyceridemia (SHTG). The curated news collection provides essential context on trial designs, scientific publications, and market developments relevant to 89Bio's glycoPEGylated FGF21 analog platform.
All content is rigorously verified to ensure compliance with financial disclosure regulations. Bookmark this page for structured access to 89Bio's progress in addressing critical unmet medical needs through innovative biopharmaceutical research.
FAQ
What is the current stock price of 89Bio (ETNB)?
What is the market cap of 89Bio (ETNB)?
